Trials / Recruiting
RecruitingNCT06296706
A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer
A Multicenter, Randomized, Controlled Phase III Clinical Study of Docetaxel for Injection (Albumin-bound) Versus Taxotere in Gastric Cancer
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 630 (estimated)
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This trial is a multicenter, randomized, controlled phase Ш clinical study of comparison of Docetaxel for Injection (Albumin-bound) and Taxotere in locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma with previous first-line treatment failure.
Detailed description
About 630 patients with locally advanced or metastatic gastric adenocarcinoma or gastric esophageal junction adenocarcinoma will be randomly assigned to the test group or the control group. All patients will receive Docetaxel for injection (Albumin-bound) or Taxotere for treatment until disease progression. Regular visits and imaging examinations will be conducted to compare the efficacy and safety of the two groups.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel for injection (Albumin-bound) | Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks |
| DRUG | Taxotere (docetaxel) | Taxotere, by intravenous infusion, every 3 weeks. |
Timeline
- Start date
- 2024-02-27
- Primary completion
- 2026-06-01
- Completion
- 2027-06-01
- First posted
- 2024-03-06
- Last updated
- 2024-11-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06296706. Inclusion in this directory is not an endorsement.